Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q2 2019 · 10-Q
Revenue$0.00$0.00— vs Q2 2018 Net Income-$2.33M-$2.33MN/M vs Q2 2018 EPS Diluted-$0.31-$0.31N/M vs Q2 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
-$2,325,172
N/M
Operating Cash Flowderived-$1,657,945N/M Free Cash Flowderived-$1,657,944N/M ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end